Rituximab as a dual therapeutic option for pemphigus and primary cutaneous B-cell lymphomas: Two case reports

Andrea Michelerio, Mattia Novario, Stefania Barruscotti, Camilla Vassallo

Research output: Contribution to journalArticle

Abstract

It is known that individuals with immune dysregulation have an increased risk of non-Hodgkin lymphoma. This association has been proven for pemphigus as well as for other autoimmune disease. We describe the development of cutaneous B-cell lymphoma in two patients affected by long-standing pemphigus vulgaris and pemphigus foliaceus (i.e., characterized by histological and immunopathological features different from those of paraneoplastic pemphigus). In both cases, a therapy with rituximab allowed to achieve the complete remission for the lymphoproliferative disease (never recurred at follow up) and a substantial long-term improvement of the clinical manifestations of pemphigus, although persistent to serological disease and occasional recurrences. We suggest that clinicians should consider that patients with long-standing pemphigus, both vulgaris and foliaceus, may develop primary cutaneous B-cell lymphomas, as shown in our report, and in these cases the treatment with rituximab is elective, providing a therapeutic option for both low-grade or follicular, CD20-positive, B-cell non-Hodgkin lymphomas and pemphigus. Nevertheless, as shown in our cases, a constant surveillance for pemphigus is necessary.

Original languageEnglish
Article numbere12948
JournalDermatologic Therapy
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Pemphigus
B-Cell Lymphoma
Skin
Therapeutics
Non-Hodgkin's Lymphoma
Rituximab
Autoimmune Diseases
Recurrence

Keywords

  • autoimmune disease
  • lymphoma
  • pemphigus
  • rituximab

ASJC Scopus subject areas

  • Dermatology

Cite this

@article{8f90b90f4f1f468fb271094c8e91a562,
title = "Rituximab as a dual therapeutic option for pemphigus and primary cutaneous B-cell lymphomas: Two case reports",
abstract = "It is known that individuals with immune dysregulation have an increased risk of non-Hodgkin lymphoma. This association has been proven for pemphigus as well as for other autoimmune disease. We describe the development of cutaneous B-cell lymphoma in two patients affected by long-standing pemphigus vulgaris and pemphigus foliaceus (i.e., characterized by histological and immunopathological features different from those of paraneoplastic pemphigus). In both cases, a therapy with rituximab allowed to achieve the complete remission for the lymphoproliferative disease (never recurred at follow up) and a substantial long-term improvement of the clinical manifestations of pemphigus, although persistent to serological disease and occasional recurrences. We suggest that clinicians should consider that patients with long-standing pemphigus, both vulgaris and foliaceus, may develop primary cutaneous B-cell lymphomas, as shown in our report, and in these cases the treatment with rituximab is elective, providing a therapeutic option for both low-grade or follicular, CD20-positive, B-cell non-Hodgkin lymphomas and pemphigus. Nevertheless, as shown in our cases, a constant surveillance for pemphigus is necessary.",
keywords = "autoimmune disease, lymphoma, pemphigus, rituximab",
author = "Andrea Michelerio and Mattia Novario and Stefania Barruscotti and Camilla Vassallo",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/dth.12948",
language = "English",
journal = "Dermatologic Therapy",
issn = "1396-0296",
publisher = "Blackwell Publishing Inc.",

}

TY - JOUR

T1 - Rituximab as a dual therapeutic option for pemphigus and primary cutaneous B-cell lymphomas

T2 - Two case reports

AU - Michelerio, Andrea

AU - Novario, Mattia

AU - Barruscotti, Stefania

AU - Vassallo, Camilla

PY - 2019/1/1

Y1 - 2019/1/1

N2 - It is known that individuals with immune dysregulation have an increased risk of non-Hodgkin lymphoma. This association has been proven for pemphigus as well as for other autoimmune disease. We describe the development of cutaneous B-cell lymphoma in two patients affected by long-standing pemphigus vulgaris and pemphigus foliaceus (i.e., characterized by histological and immunopathological features different from those of paraneoplastic pemphigus). In both cases, a therapy with rituximab allowed to achieve the complete remission for the lymphoproliferative disease (never recurred at follow up) and a substantial long-term improvement of the clinical manifestations of pemphigus, although persistent to serological disease and occasional recurrences. We suggest that clinicians should consider that patients with long-standing pemphigus, both vulgaris and foliaceus, may develop primary cutaneous B-cell lymphomas, as shown in our report, and in these cases the treatment with rituximab is elective, providing a therapeutic option for both low-grade or follicular, CD20-positive, B-cell non-Hodgkin lymphomas and pemphigus. Nevertheless, as shown in our cases, a constant surveillance for pemphigus is necessary.

AB - It is known that individuals with immune dysregulation have an increased risk of non-Hodgkin lymphoma. This association has been proven for pemphigus as well as for other autoimmune disease. We describe the development of cutaneous B-cell lymphoma in two patients affected by long-standing pemphigus vulgaris and pemphigus foliaceus (i.e., characterized by histological and immunopathological features different from those of paraneoplastic pemphigus). In both cases, a therapy with rituximab allowed to achieve the complete remission for the lymphoproliferative disease (never recurred at follow up) and a substantial long-term improvement of the clinical manifestations of pemphigus, although persistent to serological disease and occasional recurrences. We suggest that clinicians should consider that patients with long-standing pemphigus, both vulgaris and foliaceus, may develop primary cutaneous B-cell lymphomas, as shown in our report, and in these cases the treatment with rituximab is elective, providing a therapeutic option for both low-grade or follicular, CD20-positive, B-cell non-Hodgkin lymphomas and pemphigus. Nevertheless, as shown in our cases, a constant surveillance for pemphigus is necessary.

KW - autoimmune disease

KW - lymphoma

KW - pemphigus

KW - rituximab

UR - http://www.scopus.com/inward/record.url?scp=85065464462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065464462&partnerID=8YFLogxK

U2 - 10.1111/dth.12948

DO - 10.1111/dth.12948

M3 - Article

C2 - 31025498

AN - SCOPUS:85065464462

JO - Dermatologic Therapy

JF - Dermatologic Therapy

SN - 1396-0296

M1 - e12948

ER -